Predi-LYNCH
Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome
This project revolves around two objectives:
- To assess several promising technologies based on non-invasive liquid biopsies, using an innovative clinical trial protocol.
- To detect at an early stage the three most common types of cancer associated with Lynch syndrome.
Mev Dominguez ; Oslo University Hospital
European Commission Horizon Europe Mission on Cancer
Oslo University Hospital ; Tampere University, University of Edinburgh ; Institut Curie ; The University Institute of Cancerology AP-HP Sorbonne University ; University of Oslo ; Instituto de Investigação e Inovação em Saúde ; Utrecht University ; Universidad de Granada ; Aix-Marseille Université ; Rīga Stradiņš University ; Fondazione IRCCS Istituto Nazionale dei Tumori ; Klinički bolnički centar ; MSInsight ; Masaryk Memorial Cancer Institute ; Erasmus MC ; Institut Gustave Roussy ; Oslo Cancer Cluster ; Unicancer ; Evita ; Eit Health ; Elypta ; PredictBy ; Europacolon Portugal ; SemiColon ; Euregha ; Geneton ; UDG Alliance
There is an urgent need to improve early cancer detection in LS for validating and scaling-up targeted non-invasive testing modalities to stratify LS carriers for invasive procedures, for which targeting the entire LS population remains too resource-intensive and economically ineffective
Predi-LYNCH will conduct a multicentre randomised controlled trial (RCT) using advanced diagnostic techniques, combined with standard tests to enhance potential and reduce costs.
Predi-LYNCH aims to improve the care of people with Lynch syndrome (LS) by developing and implementing innovative, non-invasive early detection methods for colorectal, endometrial and urothelial cancers in these patients.
Project in the launch phase
Advancing early detection and personalized prevention of Lynch syndrome.https://predi-lynch.eu/
== Image